Page 445 - Essential Haematology

Index

Note: page numbers in italics refer to figures, those in bold refer to tables
A organ infi ltration 224–5 treatment 183, 186–9
A blood group 401 pathogenesis 224 protocols 164
gene 399 Philadelphia chromosome (Ph) stratifi cation 186–7
abciximab, venous thrombosis 379 228, 232 WHO classifi cation 180–1,
ABO blood group 367, 399, 400, ploidy 227 427–8
401 prognosis 232, 233 acute phase proteins 392, 394
determination 405 relapse 232, 233 acute promyelocytic leukaemia
ABO haemolytic disease of the remission induction 229, 231 182–3
newborn 422 treatment 187, 228–9, 230, haemorrhagic syndrome 183
ABO-incompatible blood 84 231–3 ADAMTS13 319, 337, 338, 339
aciclovir 170–1 adult therapy 232–3 adenosine triphosphate (ATP) 22,
actin 22 protocols 164 23
activated partial thromboplastin acute myeloid leukaemia (AML) binding site blocking by tyrosine
time (aPTT) 327, 328 FACS analysis 186 kinase inhibitors 195, 196
factor IX defi ciency 352 acute myeloid leukemia (AML) S-adenosyl homocysteine 67
factor V Leiden mutation 365 151, 179–90, 186 S-adenosyl methionine 67
haemophilia A 348 classifi cation 180–1, 427–8 adhesion molecules 13
lupus anticoagulant 369 clinical features 181, 182, 183 adult T-cell leukaemia/lymphoma
neonates 418 CML transformation 199 (ATLL) 153, 243, 270
thrombophilia screening 370 cytogenetics 179, 181, 182–3 African iron overload 53
vitamin K defi ciency 355 diagnostic tests 180 AIDS
activated protein C (APC) 325 diff erentiation syndrome 183 diffuse large B-cell lymphomas

disseminated intravascular genetic abnormalities 155, 159 267, 268
coagulation 358 haemorrhagic syndrome 183 haemophilia A 346, 348
resistance 364–6 immunological markers 179, 180 see also HIV infection
acute hyperviscosity syndrome 265 incidence 179–80 alcohol consumption
acute leukaemia, diagnosis 179, 180 investigations 181, 184–5, 186 haemolytic anaemia with
acute lymphoblastic leukaemia minimal residual disease 187 intoxication 387
(ALL) 153, 224–33 molecular genetics 182–3 macrocytic anaemia 71–2
BCR-ABL1 positive 233 nucleophosmin gene 157 alemtuzumab 139, 140
classifi cation 224 outcome 189 aplastic anaemia 293
clinical features 224–5 patients over 70 years of age alkylating agents, haematological
CNS-directed therapy 231 188–9 malignancies 172–3, 174
cytogenetics 227–8 prognosis 186–7 allergic reactions, non-haemolytic to
diff erential diagnosis 227 prognostic factors 181 blood transfusions 407
incidence 224 progression from myelodysplasia allopurinol, primary myelofi brosis
investigations 225–7 215 211
maintenance therapy 231–2 relapse treatment 189 aminocaproic acid 332
minimal residual disease 229, stem cell transplantation 188 δ-aminolevulinic acid synthase
230, 231, 232 survival 189 (ALA-S) 35–6
molecular genetics 227–8 therapy-related 179, 180 gene mutations 47

Essential Haematology, 6th Edition. © A. V. Hoffbrand and P. A. H. Moss. Published 2011 by Blackwell Publishing Ltd.